News

Teva advised ANP that after performing certain steps in the development process, ATL1102 was determined to no longer be in line with Teva’s preferred product profile. ANP understands

Mr Weaving joined Aceto in 1984 and over the years has held various positions in the specialty chemicals business segment. Vincent Miata, president and CEO at Aceto, said:

The US Secretary of Health and Human Services has declared a public health emergency because of the outbreak of the pandemic flu virus. The FDA has issued emergency

Cell Therapeutics develops, acquires, and commercialises oncology products for cancer treatment. The complaint charges Cell Therapeutics and certain of its officers and executives with violations of the Exchange

The study is thought to be the first ever demonstration in humans of targeted siRNA-containing nanoparticle delivery to tumors using systemic administration, delivery of functional siRNAs, and achievement

DuoPlavin/DuoCover is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). It is a fixed dose combination medicinal product

The new service is based on an 80-gene signature that identifies the basal-like, luminal-like, and HER2 molecular subtypes in breast cancer tumors. MammaPrint is the breast cancer recurrence

Reportedly, the agreement gives Novartis exclusive rights to Morphogenesis’ proprietary canine and feline cancer cell lines as well as its patented cancer vaccine technology. Morphogenesis and Novartis will

The FDA enforcement action will likely result in a consent decree, under which a third party would inspect and review the plant’s operation for an extended period and